TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT00652288

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Insulin analogs (Aspart and Detemir)
Description: Drugs given in the same injection
Study: NCT01638468

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: AngioJet Ultra PE Thrombectomy System
Description: Thrombectomy with or without lytic delivery using the AngioJet Ultra PE Thrombectomy System
Study: NCT03786094

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Eribulin
Description: Eribulin alone

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Eribulin
Description: Eribulin alone
Study: NCT03011892

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ruxolitinib 1.5% Cream BID
Description: Ruxolitinib 1.5% cream BID

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ruxolitinib 1.5% Cream BID
Description: Ruxolitinib 1.5% cream BID

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ruxolitinib 1.5% Cream BID
Description: Ruxolitinib 1.5% cream BID

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ruxolitinib 1.5% Cream BID
Description: Ruxolitinib 1.5% cream BID

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ruxolitinib 1.5% Cream BID
Description: Ruxolitinib 1.5% cream BID

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ruxolitinib 1.5% Cream BID
Description: Ruxolitinib 1.5% cream BID

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Ruxolitinib 1.5% Cream BID
Description: Ruxolitinib 1.5% cream BID

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Triamcinolone 0.1% Cream BID
Description: Triamcinolone 0.1% cream BID

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Vehicle Cream BID
Description: Vehicle cream BID

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Vehicle Cream BID
Description: Vehicle cream BID
Study: NCT03240744

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Inactivated EV71 vaccine (human diploid cell, KMB-17)
Description: 3.0 EU of inactivated enterovirus 71 vaccine (KMB-17) on day 0, 28.
Study: NCT02102503

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Standard Treatment

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Standard Treatment

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: MI and Medication review
Study: NCT02671916

Intervention type: BEHAVIORAL
Intervention: questionnaire
Description: Investigation on all study patients, no Intervention, no groups
Study: NCT03381729

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Onasemnogene Abeparvovec-xioi
Description: Self-complementary AAV9 carrying the SMN gene under the control of a hybrid CMV enhancer/chicken-β-actin promoter

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Onasemnogene Abeparvovec-xioi
Description: Self-complementary AAV9 carrying the SMN gene under the control of a hybrid CMV enhancer/chicken-β-actin promoter

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Onasemnogene Abeparvovec-xioi
Description: Self-complementary AAV9 carrying the SMN gene under the control of a hybrid CMV enhancer/chicken-β-actin promoter
Study: NCT02472509

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ursodeoxycholic Acid
Description: Patients will be commenced on UDCA 15mg/kg/day (maximum dose 900mg/day) in 2-3 divided doses for 12 months.~Patients who are unable to tolerate tablet medication will be started on UDCA syrup at the same dose.
Study: NCT02442401

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: The negative pressure wound therapy
Study: NCT03120455

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Almond Group
Description: Obese or overweight female adults will be randomly allocated to have almond as afternoon snacks, while they have a hypoenergetic diet.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Pistachio Group
Description: Obese or overweight female adults will be randomly allocated to have Pistachio as afternoon snacks, while they have a hypoenergetic diet.

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Nut free group
Description: Obese or overweight female adults will be asked to avoid nuts, seeds and nut products, while they have a hypoenergetic diet.
Study: NCT01552733

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: 'Inmotion Arm Robot'
Description: To improve limb function in those with limb impairment

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Standard of care
Description: Rehabilitation Therapy
Study: NCT02292901

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Macintosh laryngoscope

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: McGrath Mac videolaryngoscope
Study: NCT03786094

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Balixafortide
Description: Balixafortide + Eribulin
Study: NCT04081519

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: active rTMS over DLPFC
Description: 15 sessions of active rTMS over DLPFC
Study: NCT03904680

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Methotrexate
Description: Methotrexate 2.5 mg tablet

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Vitamin D
Description: Vitamin D 200,000 IU ampules
Study: NCT01133743

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lenalidomide and Dexamethasone
Description: Starting Lenalidomide dose 2.5 mgs or 5 mgs (based on baseline calculated creatinine clearance)PO daily on a 28 day cycle. Dose escalations will take place at the start of subsequent cycles as frequently as tolerated but not more frequently than at the start of each cycle to a target dose of 25mg daily. Oral dexamethasone at 12 mg PO daily will be administered on days 1-7, 14 and 21 of each cycle
Study: NCT01296906

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Recall conducted by private practices
Description: All practices in these counties will receive training on practice-based R/R using the Colorado Immunization Information System (CIIS or immunization registry). Practices will receive a recommended schedule for conducting recall in 19-35 month children and educational materials to use within their practices to promote compliance with the infant vaccination schedule. Individual practices will make their own decisions about the extent to which they follow the recommendations and implement recall within their practice. Although the study team will not provide them with any additional interventions, we will track any other interventions they independently do (websites, newsletters, telephone informational systems) in order to assess the effect of these additional interventions.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Recall conducted centrally by local health department
Description: A centralized recall of children 19-35 months will be conducted through local health departments. CIIS will identify a cohort of 19-35 month olds with an who are in need of an immunization and will coordinate up to 3 mailers to children who are not current for recommended immunizations.
Study: NCT01644877

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: DAS181 dry powder, formulation F02

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Lactose Placebo
Study: NCT04268030

Intervention type: OTHER
Intervention: collection of LFPs
Description: collection of local field potentials (LFPs) at rest and during hand opening and closing
Study: NCT03202654

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Corn Oil
Description: 4 tablespoons/day of corn oil for 4-week treatment period.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Coconut Oil
Description: 4 tablespoons/day of coconut oil for 4-week treatment period.
Study: NCT04161040

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Performance-based incentives
Description: Participants will earn $1 per minute of engagement in physical activity.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Performance-based incentives
Description: Participants will earn $1 per minute of engagement in physical activity.
Study: NCT01526148

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lithium
Description: Lithium will be initiated at 300 mg per day and titrated in 300 mg increments every 7days as tolerated with blood lithium levels \> 0.6mEq/L.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Quetiapine
Description: Quetiapine will be started at 50 mg per day at bedtime and titrated up to 300 mg as tolerated over 1 week.
Study: NCT05344547

Intervention type: DIAGNOSTIC_TEST
Intervention: Cardiac risk ratio (CRR)
Description: Cardiac risk ratio (CRR) was calculated according to Genest et al. (23) as serum total cholesterol (TC) level divided by serum high-density lipoprotein-cholesterol (HDL-c) level and woman with CRR at ≥3.5 was considered at risk of cardiac disease (24).

Intervention type: DIAGNOSTIC_TEST
Intervention: Cardiac risk ratio (CRR)
Description: Cardiac risk ratio (CRR) was calculated according to Genest et al. (23) as serum total cholesterol (TC) level divided by serum high-density lipoprotein-cholesterol (HDL-c) level and woman with CRR at ≥3.5 was considered at risk of cardiac disease (24).
Study: NCT02298101

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Technetium-99m - Diethylenetriaminepentaacetic acid
Description: Solution placed on the nebulizer reservoir

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Technetium-99m - Diethylenetriaminepentaacetic acid
Description: Solution placed on the nebulizer reservoir

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Aeroneb Solo Adapter
Description: Nebulizer

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Opti-Mist Plus Nebulizer
Description: Standard jet nebulizer

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Planar scintigraphy
Description: Imaging technique to investigate whole lung deposition

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Planar scintigraphy
Description: Imaging technique to investigate whole lung deposition

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Single photon emission computed tomography
Description: Imaging technique to investigate regional pulmonary deposition

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Single photon emission computed tomography
Description: Imaging technique to investigate regional pulmonary deposition
Study: NCT00652288

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Insulin analogs (Lispro and Glargine)
Description: Drugs given separately

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Insulin analogs (Lispro and Glargine)
Description: Drugs given in single injection
Study: NCT01926821

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sonifilan
Description: Sonifilan inj 20mg Intra muscular injection, twice per week for 8 weeks, total 16 times
Study: NCT03594552

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Arbaclofen_15
Description: Single oral dose (15mg)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Arbaclofen_15
Description: Single oral dose (15mg)
Study: NCT04081519

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: active rTMS over DLPFC
Description: 15 sessions of active rTMS over DLPFC

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: active rTMS over DLPFC
Description: 15 sessions of active rTMS over DLPFC

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Add-on active rTMS over DLPFC
Description: 15 additional sessions of active rTMS over DLPFC
Study: NCT03037697

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: TheraTogs Arm
Description: TheraTogs Arm Received Soft Orthotic undergarments

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Traditional Treatment
Description: Traditional treatment to Dyskinetic CP~1- Trunk control exercises 2- Core stability training 3- Proximal dynamic stability for the shoulder and pelvic girdles components. 4- Back and abdominal strengthening exercises 5- Standing exercises : - Standing alone gradually increase time. - Stride standing alone. - Step standing alone (other limb supported on wooden step then soft step and finally on small ball). - Standing on balance board
Study: NCT04081519

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Add-on active rTMS over LPC
Description: 15 additional sessions of active rTMS over LPC
Study: NCT03037697

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Traditional Treatment
Description: Traditional treatment to Dyskinetic CP~1- Trunk control exercises 2- Core stability training 3- Proximal dynamic stability for the shoulder and pelvic girdles components. 4- Back and abdominal strengthening exercises 5- Standing exercises : - Standing alone gradually increase time. - Stride standing alone. - Step standing alone (other limb supported on wooden step then soft step and finally on small ball). - Standing on balance board
Study: NCT04513418

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Preoperative immunonutrition
Description: Preoperative immunonutrition includes an omega-3 fatty-acid enriched enteral nutritional emulsion given by oral intake, nasogastric feeding tube or jejunostomy 600ml per day, lasting for the whole period of neoadjuvant chemoradiation. Meanwhile, oral intake is encouraged to reach 25-30kcal/kg through regular food.
Study: NCT03782779

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Breathing program and regular exercise
Description: This program will be supervised by a physical therapist and will include learning and performing a diaphragmatic-abdominal breathing, and incorporating the new breathing pattern to a upper and lower limbs regular exercises as well as to daily life activities.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Regular Exercise
Description: Regular upper and lower limbs exercises supervised by a physical therapist
Study: NCT01547377

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: zinc and selenium supplementation
Description: Data from patients were obtained at beginning and after four months of treatment with 10 mg rosuvastatin, concomitantly with zinc (30mg/d) and selenium (150μg/d) supplementation or placebo. The anthropometric and dietary data, zinc and selenium concentrations in plasma and erythrocyte, lipid profile, electronegative LDL (LDL(-)), anti- electronegative LDL, Ac-LDL(-) immune complexes, GPx and SOD activities, IL-6 and hs-CRP were evaluated in all patients

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: rosuvastatin + placebo
Description: Data from patients were obtained at beginning and after four months of treatment with 10 mg rosuvastatin, concomitantly with zinc (30mg/d) and selenium (150μg/d) supplementation or placebo. The anthropometric and dietary data, zinc and selenium concentrations in plasma and erythrocyte, lipid profile, electronegative LDL (LDL(-)), anti- electronegative LDL, Ac-LDL(-) immune complexes, GPx and SOD activities, IL-6 and hs-CRP were evaluated in all patients
Study: NCT01218672

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Photoselective Vaporization of the Prostate
Description: GreenLight XPS laser console GreenLight XPS consists of a 532 nm laser console capable of achieving power outputs between 20W and 180W. Laser technology is used to vaporize tissue for debulking prostatic hyperplasia and improvement of lower urinary tract symptoms. The 532 nm wavelength is in the visible spectrum as green light and is strongly absorbed by oxyhemoglobin.~GreenLight XPS will be used in conjunction with the MoXy™ fiber. The fiber features a side firing mechanism delivering up to180W of 532 nm light to vaporize and coagulate the prostate tissue. The fiber is guided to the treatment site by the continuous flow cystoscope, consisting of an inner and outer sheath set, 30ْ forward oblique telescope and visual obturator.

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Transurethral Resection of the Prostate
Description: Monopolar and bipolar loop TURP Systems The TURP procedure requires the use of a resectoscope, camera system and irrigation fluid. The system consists of a generator unit and a wire loop with an electrical current running through the loop used to cut prostate tissue and cauterize. Prostate tissue is cut away in small pieces and removed at the end of the procedure using irrigation. There are many manufacturers of TURP systems. Any monopolar and bipolar loop system that carry the CE mark may be used for the study.
Study: NCT00407147

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Procalcitonin assay - B.R.A.H.M.S PCT sensitive Kryptor
Description: antibiotic treatment based on clinical decision making with traditional thought processes used in both groups. In addition the physician will be given access to Procalcitonin values with recommended thresholds for likelihood of infection.
Study: NCT03401086

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Kinesio Taping
Description: Kinesio Taping
Study: NCT03218137

Intervention type: DRUG
Group type: OTHER
Intervention: Adenosine
Description: Adenosine: 0.84 mg/kg (140 mcg/kg/minute IV for 6 minutes) Verapamil 0.15 mg/kg
Study: NCT01481363

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: The Talking Sense manual
Description: Talking Sense is a recently written therapy manual for professionals to use with carers of people with dementia. It is intended to be used one to one with carers and is individualisable according to their relatives degree of communication difficulty or the extent to which the carer experiences difficulty with communication. The approach addresses the carers knowledge, skills, thinking and behaviour in a series of interdependent steps. In this study it will be delivered to carers during 3 home visits and up to a total of 4.5 hours.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Treatment as usual - communication information and advice
Description: Carers will receive the existing model of support provided by the speech and language therapy service. This is based on a one hour visit during which questions will be answered and specific advice given. No leaflets or manual will be used.
Study: NCT03985267

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mindfulness based Swinging Effect Intervention
Description: Participants will receive psycho-education about mindfulness and how it operates. That will also assist patients to warm up for the actual intervention. Then the actual swinging effect intervention will commence respectively.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Mindfulness based Swinging Effect Intervention
Description: Participants will receive psycho-education about mindfulness and how it operates. That will also assist patients to warm up for the actual intervention. Then the actual swinging effect intervention will commence respectively.
Study: NCT04468867

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Automated whole breast ultrasound
Description: This will be performed by a band 6 radiographer and will be done at baseline, post 2 cycles of chemotherapy and end of treatment chemotherapy

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Breast MRI
Description: This will be performed by band 6 or 7 radiographer with MRI training
Study: NCT00840411

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Clarithromycin ER 500 mg tablets
Description: 1 x 500 mg

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: BIAXIN® XL 500 mg tablets
Description: 1 x 500 mg
Study: NCT02740647

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Amoxicillin Clavulanate
Description: getting intra-venous1GR Amoxicillin Clavulanate 3 times a day for 5 days post surgery

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 50 ml of 0.9% sodium chloride three times a day
Study: NCT02149693

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: high-fidelity simulation and teamwork training

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: traditional resuscitation training
Study: NCT01026623

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Cixutumumab
Description: Given IV

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Diagnostic Laboratory Biomarker Analysis
Description: Correlative studies

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Temsirolimus
Description: Given IV
Study: NCT00944424

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel + High dose Vitamin D2
Description: Docetaxel + High dose Vitamin D2

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Docetaxel + Standard dose Vitamin D2
Description: Docetaxel + Standard dose Vitamin D2
Study: NCT02313064

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: CXA-10
Description: Part A has sequential single ascending doses will be administered in up to 5 cohorts of subjects. Each cohort of subjects will be randomized to receive a single dose of CXA-10 or placebo in, a fasted state. Part B has 2 periods and subjects will receive two doses of the selected dose of CXA-10.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: CXA-10 placebo
Study: NCT04852380

Intervention type: PROCEDURE
Intervention: PRP injections
Description: The 5 mL PRP concentrate was injected every week for three times, starting from recruitment. The patient was placed supine whit a knee flexion of 90°.All the procedures were carried out in an aseptic condition, injected in the knee soft spot through an anterior approach, using a 21-gauge needle.
Study: NCT04236401

Intervention type: PROCEDURE
Group type: OTHER
Intervention: electrosurgery will be used for abdominal incision
Description: electrosurgery will be used to open anterior abdominal wall and electrosurgery will be used for heamostasis also

Intervention type: PROCEDURE
Group type: OTHER
Intervention: scalpel will be used for abdominal incision
Description: scalpel will be used for abdominal wall incision and thread will be used for haemostsis